SS-31 vs Humanin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. Being developed for heart failure and mitochondrial diseases.
Also: HN, HNG (S14G-humanin)
A mitochondria-derived peptide discovered for its neuroprotective effects against Alzheimer's-related toxicity. Being studied for aging and metabolic benefits.
Key Comparison Insights
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (Human Trials) compared to Humanin (Animal Studies).
Detailed Comparison
| Attribute | SS-31 | Humanin |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. | Humanin acts through multiple pathways including STAT3 signaling, binding to IGFBP-3, and activating the FPRL1 receptor. It protects neurons from apoptosis, improves insulin sensitivity, and has anti-inflammatory effects. |
| Common Dosing | 10-40 mg daily Once or twice daily | 5-10 mg weekly divided into 2-3 injections 2-3x weekly (e.g., Monday, Wednesday, Friday) |
| Administration | Subcutaneous injection or IV infusion | Injection (route varies) |
| Typical Duration | Variable by condition | Variable |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 2/3 trials for Barth syndrome and heart failure. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. Demonstrates benefits in ischemia-reperfusion injury models. | Research shows protection against amyloid-beta toxicity in Alzheimer's models. Studies demonstrate improved insulin sensitivity, reduced atherosclerosis in animal models, and potential anti-aging effects. Human studies are limited. |
Frequently Asked Questions: SS-31 vs Humanin
What is the difference between SS-31 and Humanin?
SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. being developed for heart failure and mitochondrial diseases. Humanin is a anti-aging peptide that a mitochondria-derived peptide discovered for its neuroprotective effects against alzheimer's-related toxicity. being studied for aging and metabolic benefits. The main differences lie in their mechanisms of action and clinical applications.
Which is better, SS-31 or Humanin?
Neither is universally "better" - the choice depends on your specific goals. SS-31 is typically used for anti-aging purposes, while Humanin is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can SS-31 and Humanin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using SS-31 and Humanin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of SS-31 and Humanin is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.